Eli Lilly and Company has signed an expanded licensing deal worth up to $1 billion with Chinese biotech company Innovent Biologics for their jointly developed Tyvyt (sintilimab injection), an approved blood cancer drug in China. The expanded deal gives the US pharma giant the rights to Tyvyt or geographies outside of China. Innovent Biologics and […]
Innovent Biologics has dosed the first patient in a phase 2 trial of parsaclisib (IBI-376), a novel and selective PI3Kδ inhibitor in follicular lymphoma (FL). The goal of the study being held in China is to assess the efficacy and safety of parsaclisib in patients having recurrent or refractory follicular lymphoma or marginal zone lymphoma […]
Delaware-based pharma company Incyte has secured priority review for pemigatinib from the US Food and Drug Administration (FDA) for the treatment of locally advanced or metastatic cholangiocarcinoma. The priority review for pemigatinib is for the treatment of the condition in previously treated patients having FGFR2 fusions or rearrangements. Cholangiocarcinoma is a rare cancer that occurs […]
Innovent Biologics and Beijing Hanmi Pharmaceutical, a subsidiary of Hanmi Pharmaceutical, said that the first patient has been dosed in a phase 1 clinical trial in China for evaluating IBI315 for the treatment of advanced solid malignancies. IBI315, which has been co-developed by the companies, is a recombinant fully human bispecific antibody targeting programmed cell […]
Innovent Biologics and Shenzhen Chipscreen Biosciences have entered into a major collaboration to assess the potential of a combination therapy for advanced colorectal cancer. The combination will include Innovent’s Tyvyt (sintilimab injection), a PD-1 monoclonal antibody, alongside IBI305, a proposed biosimilar to Roche’s bevacizumab. These two drugs will be evaluated alongside Chidamide, an epigenetic modulator […]
Innovent Biologics, a leading Chinese biopharma company, has struck a landmark deal with Incyte, a prominent US pharmaceutical firm, to develop and commercialize three investigational cancer drugs. The agreement, valued at up to $391.5 million, covers pemigatinib, a FGFR1/2/3 inhibitor; itacitinib, a JAK1 inhibitor; and parsaclisib, a PI3Kδ inhibitor, which are currently in clinical stages. […]